Contact Information: Contact: Zackary Irani Tel: 949-645-2111
Biomerica Receives CE Mark Approval for 5-Minute Home Test for Kidney Disease Screening for Diabetic and Hypertensive Individuals
| Source: Biomerica
NEWPORT BEACH, CA--(Marketwire - April 21, 2009) - Biomerica, Inc. (OTCBB : BMRA ) announced
that it has received approval to CE mark its 5-minute home diagnostic test
for detecting Microalbumin, micro amounts of albumin in urine. Albumin is
normally found in the blood and filtered by the kidneys. When the kidneys
are working properly, albumin is not present in urine in significant
amounts. However, when the kidneys are damaged, small amounts of albumin
leak into the urine, resulting in elevated levels. With the CE-marking,
Biomerica's new one-step test can now be marketed directly to consumers
through pharmacies in the European Union.
At least 40 million people in the European Union have some degree of
chronic kidney disease (CKD) and that number is expected to double over the
next decade, according to the European Kidney Health Alliance. Worldwide,
it has been estimated that as many as 400-600 million people suffer from
CKD. The two main causes of CKD are diabetes and high blood pressure.
Early detection can help prevent the progression of kidney disease to
kidney failure. Nearly half of people with an advanced form of kidney
disease do not know they have weak or failing kidneys, according to recent
research published in the American Journal of Kidney Diseases, the official
journal of the National Kidney Foundation.
"We are already in discussions with several significant distributors in
Europe," said Zackary Irani, CEO, Biomerica. "This regulatory approval
allows us to now sell our new test to consumers throughout Europe."
Biomerica's home test, which will be marketed under the trade name "FORTEL
Urine Albumin Test," is a simple five-minute test that individuals can
perform in the privacy of their own home. The test utilizes an advanced
technology that requires only a sample of urine. The FORTEL Urine Albumin
Test is a part of BIOMERICA's line of easy to use tests designed to detect
diseases before they become catastrophic, incurable or too costly to treat.
About Biomerica (OTCBB : BMRA )
Biomerica, Inc. (www.biomerica.com) is a global medical technology company,
based in Newport Beach, CA. The Company manufactures and markets advanced
diagnostic products used at home, in hospitals, and in physicians' offices
for the early detection of medical conditions and diseases.
The Private Securities Litigation Reform Act of 1995 provides a "safe
harbor" for forward-looking statements. Certain information included in
this press release (as well as information included in oral statements or
other written statements made or to be made by Biomerica) contains
statements that are forward-looking; such as statements relating to
intended launch dates, sales potential, significant benefits, market size,
growth of business, favorable positions, expansion, expected orders,
leading market positions, anticipated future revenues or production volume
of the Company, success of product and new product offerings. Such
forward-looking information involves important risks and uncertainties that
could significantly affect anticipated results in the future, and
accordingly, such results may differ materially from those expressed in any
forward-looking statements made by or on behalf of Biomerica. The potential
risks and uncertainties include, among others, fluctuations in the
Company's operating results due to its business model and expansion plans,
downturns in international and or national economies, the Company's ability
to raise additional capital, the competitive environment in which the
Company will be competing, and the Company's dependence on strategic
relationships. The Company is under no obligation to update any
forward-looking statements after the date of this release.